Skip to main content

Værdipapirfonden Sparinvest – ophævelse suspension på alle afdelinger

Det skal herved oplyses, at det nu igen er muligt at stille indre værdier i nedenstående afdelinger, hvorfor Nykredit Portefølje Administration A/S har anmodet Nasdaq Copenhagen A/S om, at suspension ophæves.  Ophævelsen gælder nedenstående afdelinger: Fund Name ISIN Order Book CodeINDEX Bæredygtige Virksomhedsobligationer HY KL DK0016028020 SPVBVOINDEX Emerging Market Bonds Lokalvaluta DK0060254043 SPVINOINDEX Emerging Market Bonds Lokalvaluta Akk. – KL A DK0060254126 SPVINOAKKKLAINDEX Globale Aktier KL DK0060747822 SPVIGAKLINDEX Globale Aktier Min. Risiko Akk. KL DK0060748127 SPVIGAMRAKLINDEX Bæredygtige Global KL DK0060747905 SPVIBGKLINDEX Bæredygtige USA KL DK0060748200 SPVBUSAKLINDEX Bæredygtige Europa KL DK0060748044 SPVBEUKLINDEX Lav Risiko KL DK0060748556 SPVILRKLINDEX Mellem Risiko KL DK0060748630 SPVIMRKLINDEX...

Continue reading

OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting

LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it will hold a key Scientific Advisory Board (SAB) meeting with leading ophthalmology experts during the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, DC. The SAB meeting, scheduled to take place alongside the conference, will bring together prominent corneal and ocular surface disease specialists to review clinical data for the company’s lead candidate, urcosimod and provide strategic guidance on the upcoming clinical program. In conjunction with the SAB meeting, Dr. Pedram Hamrah, Professor of Ophthalmology,...

Continue reading

Highlander Silver Provides Update; Drilling Commences at Corani Silver Project

TORONTO, April 07, 2026 (GLOBE NEWSWIRE) — Highlander Silver Corp. (TSX, NYSE American: HSLV) (“Highlander Silver” or the “Company”) is pleased to provide a portfolio update following the successful completion of its combination with Bear Creek Mining (see press release dated February 26, 2026). Daniel Earle, President and CEO of Highlander Silver, commented: “Highlander Silver is well positioned to fast-track project advancement across its portfolio of high-quality silver assets. This includes a focus on high-impact exploration, project optimization, and site preparation for development of Corani, the largest fully permitted primary silver project in the world, as well as permitting at San Luis, one of the highest M&I resource grade projects in both the gold and silver sectors. As of March 31, the Company had an unaudited...

Continue reading

Baker Hughes Secures Strategic Gas Technology Order Supporting Argentina’s Gas Infrastructure

Baker Hughes to supply three NovaLT™16 gas turbines with three centrifugal compressors and related services for a pipeline project to support Argentina’s LNG exports These gas compression units mark the first use of Baker Hughes’ NovaLT™ gas turbine technology in South America, reflecting growing demand for high-efficiency, lower-emissions turbomachineryHOUSTON and LONDON, April 07, 2026 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR), an energy technology company, announced Tuesday it has secured a strategic order from San Matias Pipeline S.A. to supply three gas compression units for a major natural gas pipeline project in Argentina. The order consists of three NovaLT™16 gas turbines equipped with three centrifugal compressors, along with commissioning services, spare parts, special tools, and remote monitoring...

Continue reading

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences   Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL® Findings support ongoing VALUE Phase III study and planned expansion into DFUs and pressure ulcers YAVNE, Israel, April 7, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced multiple oral and poster presentations at three leading wound care conferences: the Wound Healing Society (WHS) and the Symposium on Advanced Wound Care (SAWC) Spring 2026, taking place April 8–12 in Charlotte, North Carolina, and the European Wound Management Association (EWMA) 2026, taking place May 6–8 in Bremen, Germany. The presentations will showcase new preclinical and clinical data supporting...

Continue reading

Plug Participating in RBC Non-Deal Roadshow in Canada

SLINGERLANDS, N.Y., April 07, 2026 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive solutions for the hydrogen economy, will participate in a non-deal roadshow hosted by RBC. The meetings will provide an opportunity for institutional investors to engage with management on Plug’s business strategy, operational execution, and path to profitability. WHEN:Tuesday, April 7, 2026 – Toronto, CanadaWednesday, April 8, 2026 – Montreal, Canada WHO:Paul Middleton, CFO, Plug Power Roberto Friedlander, Vice President of Investor Relations, Plug PowerFurther detail on Plug’s investor conference and roadshow participation is available in the investor relations section of the Company’s website: https://www.ir.plugpower.com/events-and-presentations/default.aspx. About Plug Power Plug is building the global...

Continue reading

Schouw & Co. share buy-back programme, week 14 2026

On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount DKK    Accumulated until 27 March 2026 101,283 668.66 67,723,666    Monday, 30 March 2026 1,000 649.15 649,147    Tuesday, 31 March 2026 1,000 659.00 659,000    Wednesday, 1 April 2026 1,000 668.00 668,000    Thursday, 2 April 2026 – – –    Friday,...

Continue reading

Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center

~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~ ~ This New Study and Other Independent, Institution-Led Research Continues to Expand Real-World Validation of PEDMARK® Across New Tumor Types and Patient Populations ~ RESEARCH TRIANGLE PARK, N.C., April 07, 2026 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center to evaluate use of PEDMARK® (sodium thiosulfate injection) in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin. PEDMARK® is currently approved for pediatric patients one month of age and older with...

Continue reading

Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health

National education campaign aims to educate Americans about antibodies and their role in immune health Campaign centerpiece, AntibodiesforAnyBody.com, offers an interactive immune health wellness assessment to empower people to better understand the relationship between their daily habits and immune health and wellnessNEW HAVEN, Conn., April 07, 2026 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD) today announced the launch of Antibodies for Any Body, a national education campaign designed to elevate public understanding of antibodies, one of the most important parts of the immune system, and their role in protecting against disease. The campaign launches in collaboration with renowned ski champion Lindsey Vonn, whose career has been defined by training with intention, overcoming challenges, and caring for her body from the...

Continue reading

Fury Appoints Vice President, Project Development

TORONTO, April 07, 2026 (GLOBE NEWSWIRE) — Fury Gold Mines Limited (TSX and NYSE American: FURY) (“Fury” or the “Company”) is pleased to announce the appointment of Mario Courchesne as Vice President, Project Development, effective immediately. Mr. Courchesne brings over 40 years of experience in engineering, process development, feasibility studies, due diligence, construction, operations, site infrastructure, and demolition. His extensive background provides a comprehensive understanding of all project phases within the minerals industry. He spent a significant portion of his career in the gold sector with Cambior, served as a department and project manager for engineering firms, participate in developing Stornoway Diamonds Mine from feasibility study-level to production and worked for Rio Tinto in Labrador City. He is a Mining...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.